AUG 18·SEC EDGARLow
Catalyst4, Inc. purchased $50.1M of MPLT (indirect holdings)
Catalyst4, Inc. purchased 4,400,000 indirectly-held shares of MapLight Therapeutics, Inc. (MPLT) at $11.38 ($50.07M total) on 2026-08-14.
StockNASDAQ · US · USDHealthcare · Biotechnology
$MPLT
MapLight Therapeutics, Inc.
alphai earnings readSecond quarter 2026 · AUG 13MapLight reported positive Phase 2 ZEPHYR results for ML-007C-MA in schizophrenia, continued enrollment in the Phase 2 VISTA ADP trial, and ended the quarter with $351.3 million in cash, cash equivalents and investments.Verdict: mixedRead →
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Price · $MPLTvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $MPLT in the last 7 days.
Insider · 30dAll trades →
- Buys
- $63.1M 3 txs
- Sells
- $277K 1 txs
Catalyst4, Inc.3× · $63.1M
10b5-1 share of filings25%
Top stories · $MPLTMore →
AUG 13·rttnews.com
MapLight Raises $150 M PIPE To Fund CNS Pipeline
MapLight Therapeutics (MPLT) priced a $150 million PIPE, selling 9.2M shares at $11.38 and 4.0M pre-funded warrants at $11.3799, exercisable at $0.0001 with no expiration. Proceeds will fund CNS drug ML-007C-MA, including VISTA Phase 2 in Alzheimer’s disease psychosis and ZEPHYR-2 Phase 3 in schizophrenia. Closing expected Aug. 14, 2026.
AUG 13·SEC EDGAR 8-K
MapLight Therapeutics, Inc. (MPLT): Results of Operations and Financial Condition
MapLight Therapeutics, Inc. (MPLT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Reported positive results from the potentially registrational Phase 2 ZEPHYR trial of ML-007C-MA in schizophrenia, supporting advancement into a Phase 3 ZEPHYR-2 trial Continued advancement of ML-007C-MA in ADP, with enrollment ongoing in the Phase 2 VISTA trial and
MPLT sentiment & insider activity
Recent MPLT coverage spans insider activity, corporate actions and market movers.
In the last 30 days, MPLT insiders filed 4 SEC Form 4 transactions — 3 purchases ($63.1M) and 1 sale ($277K). The most active reporter was Catalyst4, Inc. with 3 filings. 25% of those filings were made under pre-arranged Rule 10b5-1 plans.
What's driving MPLT
The filing signals a large 10% owner adding to MapLight Therapeutics, but it is not a fundamental update like guidance or trial data.
The PIPE provides runway through 2028 but is dilutive, so near-term price action may hinge on whether investors view the financing as sufficient versus dilution risk.
The filing indicates MPLT is raising capital via a private placement structure (common shares plus pre-funded warrants), which can be dilutive and may pressure near-term sentiment.
The PIPE is a near-term dilution overhang but extends runway to fund ML-007C-MA through 2028, shifting the risk balance toward clinical execution.
A 10% owner indirect open-market purchase is a bullish signal, but it is not a fundamental catalyst like guidance, trial data, or a deal.
alphai scores every news story that mentions MPLT with an AI model for sentiment and relevance, and aggregates insider trades from MapLight Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $MPLT
Score
Catalyst4, Inc. purchased $50.1M of MPLT (indirect holdings)
Catalyst4, Inc. purchased 4,400,000 indirectly-held shares of MapLight Therapeutics, Inc. (MPLT) at $11.38 ($50.07M total) on 2026-08-14.
1 min readMapLight Raises $150 M PIPE To Fund CNS Pipeline
MapLight Therapeutics (MPLT) priced a $150 million PIPE, selling 9.2M shares at $11.38 and 4.0M pre-funded warrants at $11.3799, exercisable at $0.0001 with no expiration. Proceeds will fund CNS drug ML-007C-MA, including VISTA Phase 2 in Alzheimer’s disease psychosis and ZEPHYR-2 Phase 3 in schizophrenia. Closing expected Aug. 14, 2026.
2 min readMapLight Therapeutics, Inc. (MPLT): Results of Operations and Financial Condition
MapLight Therapeutics, Inc. (MPLT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Reported positive results from the potentially registrational Phase 2 ZEPHYR trial of ML-007C-MA in schizophrenia, supporting advancement into a Phase 3 ZEPHYR-2 trial Continued advancement of ML-007C-MA in ADP, with enrollment ongoing in the Phase 2 VISTA trial and
6 min readMapLight Therapeutics, Inc.: MapLight Therapeutics Announces $150 Million Private Placement Financing
MapLight Therapeutics (Nasdaq: MPLT) announced a $150 million PIPE private placement. It will sell 9,197,887 common shares at $11.38 and pre-funded warrants for up to 3,983,168 shares at $11.3799, with an exercise price of $0.0001. Proceeds will fund ML-007C-MA (VISTA Phase 2 and ZEPHYR-2 Phase 3) and working capital. Expected close Aug. 14, 2026.
4 min readCatalyst4, Inc. purchased $15.3M of MPLT (indirect holdings)
Catalyst4, Inc. purchased 1,209,225 indirectly-held shares of MapLight Therapeutics, Inc. (MPLT) at an average of $12.66 ($10.74–$13.00, $15.31M total) across 4 trades over 2026-07-28 to 2026-07-30.
2 min readTop Biotech Gainers: KNSA Soars On Q2 Results, TRIB, OPK On Watch, MPLT On The Mend?
Biotech gainers included Trinity Biotech (TRIB), which rose 36% after Q2 results and a one-for-thirty reverse ADS split to regain Nasdaq bid compliance. OPKO Health (OPK) gained 33% on Q2 revenue of $163.5M and softer Q3/full-year guidance. Kiniksa (KNSA) jumped 25% after raising 2026 net product revenue outlook to $980M-$995M. MapLight (MPLT) rebounded 24% after mixed Phase 2 schizophrenia data. ProMIS (PMN) rose 24% on interim Alzheimer’s data; Prelude (PRLD) rose 19% without specific news.
7 min readStocks Fall from Early Highs as Chipmakers Retreat
Stocks slipped from early highs as chipmakers and AI-infrastructure shares fell. The iShares Semiconductor ETF (SOXX) fell over 3%, with Sandisk (SNDK) down more than 11% and AMD and Western Digital down over 6%. Crude dropped about 6%, lifting T-notes and lowering 10-year breakeven inflation. Software stocks rose; Workday gained over 8%.
6 min readMapLight Therapeutics director Troy Cox buys $148,702 in shares By Investing.com
MapLight Therapeutics director Troy Cox bought 15,620 shares of MPLT for $148,702 on July 28, 2026, at a weighted average price of $9.52. The stock later traded around $12.31. The article also notes multiple analyst price target cuts and rating changes tied to MapLight’s Phase 2 ZEPHYR trial results.
3 min readCox Troy purchased $149K of MPLT (indirect holdings)
Cox Troy purchased 15,620 indirectly-held shares of MapLight Therapeutics, Inc. (MPLT) at $9.52 ($0.15M total) on 2026-07-28.
1 min readMapLight Therapeutics stock crashes on Phase II schizophrenia data
MapLight Therapeutics shares fell 71.9% after it reported mixed Phase II schizophrenia trial data, dropping from $35.23 (July 23 close) to $9.90 (July 27 close). The Nasdaq-listed company raised $250m in an Oct 2025 IPO for its ZEPHYR trial. MapLight aims to compete with BMS’s Cobenfy, which GlobalData projects could reach $2.2bn in 2031.
4 min read